The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).
Stephen R. D. Johnston
No relevant relationships to disclose
Mark Basik
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Roberto Hegg
No relevant relationships to disclose
Wirote Lausoontornsiri
No relevant relationships to disclose
Lukasz Grzeda
No relevant relationships to disclose
Mark Clemons
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Lydia Mary Dreosti
No relevant relationships to disclose
Serban Ghiorghiu
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Helen Mann
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Donal Landers
Employment or Leadership Position - AstraZeneca
Mary Stuart
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Massimo Cristofanilli
No relevant relationships to disclose